CD70: An emerging target for integrated cancer diagnosis and therapy

IF 7.9 1区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Clinical and Translational Medicine Pub Date : 2025-07-09 DOI:10.1002/ctm2.70400

Jiatao Hu, Jinxin Li, Bo Yang, Siyi Wang, Yi Bao, Yiren Yang, Kun Qiao, Fei Guo, Xinxin Gan, Linhui Wang

{"title":"CD70: An emerging target for integrated cancer diagnosis and therapy","authors":"Jiatao Hu, Jinxin Li, Bo Yang, Siyi Wang, Yi Bao, Yiren Yang, Kun Qiao, Fei Guo, Xinxin Gan, Linhui Wang","doi":"10.1002/ctm2.70400","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>CD70, which is a ligand belonging to tumour necrosis factors, exhibits aberrant overexpression among multiple hematologic and solid malignancies and has drawn extensive research enthusiasm as a target to treat and diagnose cancers. CD70-targeted immuno-PET/CT is an emerging approach for cancer diagnosis, with the potential to improve tumour detection, assist disease staging, and monitor therapeutic response. CD70-targeted therapeutic approaches, involving antibody–drug conjugates, CAR-T, CAR-NK, and monoclonal antibodies, have shown encouraging activity in preclinical models and preliminary signals of efficacy in early clinical studies. In addition to these monotherapies, increasing efforts have focused on rational combination strategies that aim to enhance antitumor efficacy, reverse immune suppression, and overcome resistance. This review comprehensively summarizes the diagnostic and therapeutic advances in CD70-targeted strategies, discusses ongoing barriers, and outlines future directions to advance CD70-targeted imaging and therapeutic strategies through mechanistic research and clinical translation.</p>\n \n <section>\n \n <h3> Key points</h3>\n \n <div>\n <ul>\n \n <li>CD70 is aberrantly overexpressed in diverse malignancies with limited normal tissue expression.</li>\n \n <li>CD70-targeted immuno-PET/CT improves tumour detection, staging, and treatment monitoring.</li>\n \n <li>Multiple CD70-targeted therapies, including CAR-T and CAR-NK, are under active investigation.</li>\n \n <li>Rational combination strategies are emerging to enhance antitumor efficacy.</li>\n </ul>\n </div>\n </section>\n </section>\n </div>","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"15 7","pages":""},"PeriodicalIF":7.9000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctm2.70400","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ctm2.70400","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

CD70, which is a ligand belonging to tumour necrosis factors, exhibits aberrant overexpression among multiple hematologic and solid malignancies and has drawn extensive research enthusiasm as a target to treat and diagnose cancers. CD70-targeted immuno-PET/CT is an emerging approach for cancer diagnosis, with the potential to improve tumour detection, assist disease staging, and monitor therapeutic response. CD70-targeted therapeutic approaches, involving antibody–drug conjugates, CAR-T, CAR-NK, and monoclonal antibodies, have shown encouraging activity in preclinical models and preliminary signals of efficacy in early clinical studies. In addition to these monotherapies, increasing efforts have focused on rational combination strategies that aim to enhance antitumor efficacy, reverse immune suppression, and overcome resistance. This review comprehensively summarizes the diagnostic and therapeutic advances in CD70-targeted strategies, discusses ongoing barriers, and outlines future directions to advance CD70-targeted imaging and therapeutic strategies through mechanistic research and clinical translation.

Key points

CD70 is aberrantly overexpressed in diverse malignancies with limited normal tissue expression.
CD70-targeted immuno-PET/CT improves tumour detection, staging, and treatment monitoring.
Multiple CD70-targeted therapies, including CAR-T and CAR-NK, are under active investigation.
Rational combination strategies are emerging to enhance antitumor efficacy.

Abstract Image

查看原文本刊更多论文

CD70：癌症综合诊断和治疗的新靶点

CD70是一种属于肿瘤坏死因子的配体，在多种血液和实体恶性肿瘤中表现出异常过表达，作为治疗和诊断癌症的靶点，引起了广泛的研究热情。cd70靶向免疫pet /CT是一种新兴的癌症诊断方法，具有改善肿瘤检测、辅助疾病分期和监测治疗反应的潜力。针对cd70的治疗方法，包括抗体-药物偶联物、CAR-T、CAR-NK和单克隆抗体，在临床前模型中显示出令人鼓舞的活性，在早期临床研究中显示出初步的疗效信号。除了这些单一疗法，越来越多的努力集中在合理的联合策略，旨在提高抗肿瘤疗效，逆转免疫抑制，克服耐药性。本文全面总结了cd70靶向策略的诊断和治疗进展，讨论了目前存在的障碍，并概述了通过机制研究和临床转化推进cd70靶向成像和治疗策略的未来方向。CD70在多种恶性肿瘤中异常过表达，正常组织表达有限。cd70靶向免疫pet /CT改善了肿瘤的检测、分期和治疗监测。包括CAR-T和CAR-NK在内的多种cd70靶向治疗正在积极研究中。为提高抗肿瘤疗效，合理的联合用药策略应运而生。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Translational Medicine Multiple-

CiteScore

15.90

自引率

1.90%

发文量

450

审稿时长

4 weeks

期刊介绍： Clinical and Translational Medicine (CTM) is an international, peer-reviewed, open-access journal dedicated to accelerating the translation of preclinical research into clinical applications and fostering communication between basic and clinical scientists. It highlights the clinical potential and application of various fields including biotechnologies, biomaterials, bioengineering, biomarkers, molecular medicine, omics science, bioinformatics, immunology, molecular imaging, drug discovery, regulation, and health policy. With a focus on the bench-to-bedside approach, CTM prioritizes studies and clinical observations that generate hypotheses relevant to patients and diseases, guiding investigations in cellular and molecular medicine. The journal encourages submissions from clinicians, researchers, policymakers, and industry professionals.